<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01939899</url>
  </required_header>
  <id_info>
    <org_study_id>C16017</org_study_id>
    <secondary_id>2013-002302-32</secondary_id>
    <secondary_id>U1111-1164-7551</secondary_id>
    <secondary_id>166547</secondary_id>
    <secondary_id>REec-2016-2137</secondary_id>
    <secondary_id>13/EM/0373</secondary_id>
    <nct_id>NCT01939899</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma</brief_title>
  <official_title>An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase 2 study to evaluate the efficacy and safety of oral
      IXAZOMIB in adult patients with follicular lymphoma (FL) that is relapsed and/or refractory
      to prior treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2013</start_date>
  <completion_date type="Actual">March 23, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response (Complete Response (CR) + Partial Response(PR)) Rate (ORR)</measure>
    <time_frame>Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Approximately 8 months after dosing the first patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to a total of 24 months after first dose or until disease progression, withdrawal from study, or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Disease Control</measure>
    <time_frame>Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Time from the date of registration to the date at which the patient's objective status is first noted to be a CR or PR (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented (assessed up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates in FL patients positive versus negative for the proteasome subunit beta type-1 (PSMB1) polymorphic marker</measure>
    <time_frame>Time from the start of treatment to the occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (up to approximately 24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AE) or Serious Adverse Events (SAE)</measure>
    <time_frame>Signing of informed consent through 30 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters including Maximum Concentration (Cmax), Single-dose time to reach maximum plasma concentration (Tmax), Area under the plasma concentration versus time curve (AUC) from zero to time of last quantifiable plasma concentration (AUClast)</measure>
    <time_frame>Days 1-3, 5, 8, 15-17, 19 and 22 during Cycle 1 and Day 1 during Cycles 2-4 of each lead-in dose finding cohort</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>IXAZOMIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IXAZOMIB</intervention_name>
    <description>Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.</description>
    <arm_group_label>IXAZOMIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years or older

          -  Patients must have a pathologically confirmed diagnosis of non-Hodgkin lymphoma (NHL)
             (for the lead-in dose-finding phase) and FL (for phase 2)

          -  Patients must have radiographically or clinically measurable disease

          -  Patients must be relapsed and/or refractory after at least 1 prior therapy (excluding
             radiation) with documented progressive disease at the time of enrollment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception or agree to practice true abstinence

          -  Male patients who agree to practice effective barrier contraception or agree to
             practice true abstinence

          -  Voluntary written consent

          -  Suitable venous access

          -  Appropriate clinical laboratory values as defined in the protocol

          -  Recovered from toxicities of prior anticancer therapy

          -  If the trial proceeds to the second step on the basis of the tandem 2-step design,
             patients must be confirmed PSMB1 positive at the central laboratory before treatment

        Exclusion Criteria

          -  Peripheral neuropathy that is greater or equal to Grade 2 or Grade 1 with pain

          -  Female patients who are lactating and breastfeeding or have a positive serum pregnancy
             test during the Screening period

          -  Autologous stem cell transplant within 6 months before Day 1 of Cycle 1, or prior
             allogeneic stem cell transplant at any time

          -  Major surgery within 14 days before the first dose of study drug

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before the first dose of study drug

          -  Comorbid systemic illnesses or other severe concurrent disease that, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Evidence of current uncontrolled cardiovascular conditions including uncontrolled
             hypertension, severe uncontrolled ventricular arrhythmias, unstable angina, New York
             Heart Association (NYHA) Class III or IV cardiac disease, or myocardial infarction
             within the past 6 months

          -  Diarrhea &gt; Grade 1 on the basis of the NCI CTCAE categorization

          -  Systemic antineoplastic (including glucocorticoids &gt; the equivalent of 15 mg of
             prednisone daily), experimental, or radiation therapy within 21 days before the first
             dose of study drug

          -  Prior treatment with rituximab or other unconjugated antibody treatment within 42 days
             (21 days if clear evidence of progressive disease or immediate treatment is mandated)

          -  Treatment with radioimmunoconjugates or toxin immunoconjugates within 12 weeks before
             the first dosing of study treatment

          -  Systemic treatment with strong inhibitors of CYP1A2 or CYP3A, or strong CYP3A inducers
             within 14 days before the first dose of IXAZOMIB - Ongoing systemic therapy with
             corticosteroids

          -  Central nervous system (CNS) involvement that is clinically uncontrolled or newly
             diagnosed in the last 4 months

          -  Ongoing or active systemic viral infection, known human immunodeficiency virus(HIV)
             positive, known active hepatitis B virus or known active hepatitis C virus

          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual disease
             with the exception of nonmelanoma skin cancer or any completely resected carcinoma in
             situ

          -  Platelet transfusions within 3 days before the 1st dose of study drug

          -  Inability to swallow capsules, or inability or unwillingness to avoid taking anything
             by mouth except for water and prescribed medication for 2 hours before and 1 hour
             after dose of IXAZOMIB - Known allergy to boron or excipients in the formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2013</study_first_posted>
  <disposition_first_submitted>November 29, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 29, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 30, 2016</disposition_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MLN9708</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>IXAZOMIB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 20, 2018</submitted>
    <returned>April 18, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

